Revive Therapeutics (CSE: RVV) this morning revealed that it has received positive results for a pre-clinical study that evaluated the efficacy of psilocybin in the treatment of mild traumatic brain injury. The pre-clinical trial was conducted in a rodent model of such an injury.
Conducted by the National Health Research Institute, the study focused on characterizing the potential neuroreparative effective effect of psilocybin, as compared to a treatment with a saline using a traumatic brain injury mouse model. The pre-clinical study saw adult mice randomly assigned to four groups, which included a control, TBI+saline, TBI and low dose psilocybin, and TBI and high dose psilocybin. Cognitive function was then tested with a Morris water maze test after the injury.
In short, it was discovered that psilocybin when provided after the injury improved cognitive function in mice that had the TBI, while no adverse effects were recognized.
“We are pleased with the results from our psilocybin research study in TBI as it strengthens our intellectual property portfolio for novel uses of psilocybin and it complements our robust psilocybin-based portfolio. We are focused on advancing psilocybin to treat mild TBI, also commonly known as concussions.”
Michael Frank, CEO of Revive Therapeutics
Following the positive research results, the company has filed an international patent cooperation treat application to seek protection of the invention in 153 countries, which such jurisdictions including Canada, the U.S., Europe, China and Japan. The international patent filed is in connection with a patent recently acquired from PharmaTher, entitled “Psilocybin in the Treatment of Neurological Brain Injury.”
Revive Therapeutics last traded at $0.48 on the CSE.
FULL DISCLOSURE: Revive Therapeutics is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover Revive Therapeutics on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.
